Assessment of anxiety and depression in advanced cancer patients and their relationship with quality of life

被引:127
作者
Mystakidou, K [1 ]
Tsilika, E [1 ]
Parpa, E [1 ]
Katsouda, E [1 ]
Galanos, A [1 ]
Vlahos, L [1 ]
机构
[1] Univ Athens, Sch Med, Areteion Hosp, Dept Radiol,Pain relief & Palliat Care Unit, Athens 11526, Greece
关键词
advanced cancer patients; anxiety; depression; quality of life;
D O I
10.1007/s11136-005-4324-3
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The growing interest in the mental health and quality of life of cancer patients, has been the major reason for conducting this study. The aims were to compare advanced cancer patients' responses to Hospital Anxiety and Depression (HAD) scale with those to European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30, version 3.0), as well as the impact of quality of life dimensions (as measured by EORTC QLQ-C30) on the levels of anxiety and depression. The analysis, conducted in 120 advanced cancer patients, showed that the most significant associations were found between emotional functioning and HAD-T (total sum of scores) (r=-0.747; p < 0.0005), HAD-A (anxiety) (r=-0.725; p < 0.0005) and HAD-D (depression) (r=-0.553; p < 0.0005). In the prediction of HAD-T, the contribution of physical, emotional, role, and social functioning along with nausea-vomiting, dyspnea, sleep disturbance and gender is high. For anxiety, the predictor variables were physical, role, cognitive, emotional, and social functioning, followed by dyspnea, sleep disturbance, and appetite loss, while depression was predicted by physical, role, emotional, and social functioning, the symptoms of nausea-vomiting, pain, sleep disturbance, constipation, as well as the variables of age, gender, anticancer treatment and performance status. Concluding, psychological morbidity, in this patient population, was predominantly predicted by the emotional functioning dimension of EORTC QLQ-C30.
引用
收藏
页码:1825 / 1833
页数:9
相关论文
共 39 条
[1]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]   Prevalence of anxiety and depression in cancer patients seen at the Norwegian Radium Hospital [J].
Aass, N ;
Fossa, SD ;
Dahl, AA ;
Moe, TJ .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (10) :1597-1604
[3]   Biobehavioral outcomes following psychological interventions for cancer patients [J].
Andersen, BL .
JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY, 2002, 70 (03) :590-610
[4]  
[Anonymous], INT J CANC
[5]   THE RELATIONSHIP OF 2 DIMENSIONS OF SOCIAL SUPPORT TO THE PSYCHOLOGICAL WELL-BEING AND SOCIAL FUNCTIONING OF WOMEN WITH ADVANCED BREAST-CANCER [J].
BLOOM, JR ;
SPIEGEL, D .
SOCIAL SCIENCE & MEDICINE, 1984, 19 (08) :831-837
[6]   IDENTIFYING PATIENTS AT RISK FOR, AND TREATMENT OF MAJOR PSYCHIATRIC COMPLICATIONS OF CANCER [J].
BREITBART, W .
SUPPORTIVE CARE IN CANCER, 1995, 3 (01) :45-60
[7]   SCREENING FOR DEPRESSION AND ANXIETY IN CANCER-PATIENTS USING THE HOSPITAL ANXIETY AND DEPRESSIONS SCALE [J].
CARROLL, BT ;
KATHOL, RG ;
NOYES, R ;
WALD, TG ;
CLAMON, GH .
GENERAL HOSPITAL PSYCHIATRY, 1993, 15 (02) :69-74
[8]   Assessment of depression among cancer patients: The role of pain, cancer type and treatment [J].
Ciaramella, A ;
Poli, P .
PSYCHO-ONCOLOGY, 2001, 10 (02) :156-165
[9]   Detecting psychological distress in cancer patients: validity of the Italian version of the Hospital Anxiety and Depression Scale [J].
Costantini, M ;
Musso, M ;
Viterbori, P ;
Bonci, F ;
Del Mastro, L ;
Garrone, O ;
Venturini, M ;
Morasso, G .
SUPPORTIVE CARE IN CANCER, 1999, 7 (03) :121-127
[10]  
Dugan W, 1998, PSYCHO-ONCOLOGY, V7, P483, DOI 10.1002/(SICI)1099-1611(199811/12)7:6<483::AID-PON326>3.0.CO